|
26 Jun 2020 |
Assembly Biosciences Initiates Phase 2 Trial Evaluating Second-Generation Core Inhibitor ABI-H2158 for Chronic Hepatitis B Infection
|
|
26 Jun 2020 |
AiViva Biopharma Announces Positive Data from Phase 1/2a Clinical Trial of AIV001 for Dermal Scarring and Wound Healing
|
|
26 Jun 2020 |
Tizona Initiates Clinical Development of TTX-080 in Advanced Cancers
|
|
26 Jun 2020 |
Sosei Heptares and AbbVie Announce New Discovery Collaboration Targeting Inflammatory Diseases
|
|
25 Jun 2020 |
Moberg Pharma Meets Primary Endpoint in the European Phase 3 Study
|
|
25 Jun 2020 |
Acceleron Presents Topline Results of the PULSAR Phase 2 Trial of Sotatercept in Patients with Pulmonary Arterial Hypertension
|
|
25 Jun 2020 |
uniQure Announces License Agreement with CSL Behring to Commercialize Hemophilia B Gene Therapy
|
|
25 Jun 2020 |
Breztri Aerosphere significantly reduced rate of moderate or severe COPD exacerbations in Phase III ETHOS trial
|
|
25 Jun 2020 |
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) that is Not Curable by Surgery or Radiation
|
|
25 Jun 2020 |
Positive Results from Phase 2 WILLOW Study of Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis Presented at ATS Virtual Clinical Trials Session
|
|
25 Jun 2020 |
Sinovac Receives Approval from China for its Quadrivalent Influenza Vaccine
|
|
24 Jun 2020 |
Medigene enters Phase I clinical development with its TCR-T immunotherapy MDG1021 in hematological cancers
|
|
24 Jun 2020 |
Yumanity Therapeutics Announces Strategic Research Collaboration and License Agreement with Merck Focused on Accelerating the Development of New Treatments for Neurodegenerative Diseases
|
|
24 Jun 2020 |
Rhythm Pharmaceuticals Announces Positive Results from Phase 2 Study of Once-weekly Formulation of Setmelanotide in Healthy Obese Volunteers
|
|
24 Jun 2020 |
ChemoCentryx Identifies Novel Orally Administered Immune Checkpoint Inhibitor CCX559 for Next Generation Cancer Treatment
|
|
24 Jun 2020 |
Immunovative Therapies and Mirror Biologics Announce US FDA Clearance of a Universal Anti-Viral Vaccine Phase I/II Clinical Trial for Healthy Elderly Adults
|
|
24 Jun 2020 |
La Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc.
|
|
24 Jun 2020 |
Grid Therapeutics Announces Enrollment of First Patient in Phase 1 Study of GT103 in Refractory NSCLC Patients
|
|
24 Jun 2020 |
IM Therapeutics Announces First Patient Dosed in Phase 1 Study of Its Lead Drug IMT-002 for Type 1 Diabetes
|
|
24 Jun 2020 |
Alpine Immune Sciences Announces First Patient Dosed in NEON-1 Phase 1 Trial of ALPN-202 in Patients with Advanced Malignancies
|
